Management of status epilepticus in patients with liver or kidney disease: a narrative review

References

• Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus - report of the ILAE task force on classification of status epilepticus. Epilepsia. 2015;56:1515–1523.
   PubMed Web of Science ®Google Scholar
• Leitinger M, Trinka E, Zimmermann G, et al. Epidemiology of status epilepticus in adults: apples, pears, and oranges - a critical review. Epilepsy Behav. 2020;103:106720.
   PubMed Web of Science ®Google Scholar
• Lv RJ, Wang Q, Cui T, et al. Status epilepticus-related etiology, incidence and mortality: a meta-analysis. Epilepsy Res. 2017;136:12–17.
   PubMed Web of Science ®Google Scholar
• Minicucci F, Ferlisi M, Brigo F, et al. Management of status epilepticus in adults. Position Paper of the Italian League against Epilepsy. Epilepsy Behav. 2020;102:106675.
   PubMed Web of Science ®Google Scholar
• Asconapé JJ. Use of antiepileptic drugs in hepatic and renal disease. Handb Clin Neurol. 2014;119:417–432.
   PubMedGoogle Scholar
• Trinka E, Höfler J, Leitinger M, et al. Pharmacotherapy for status epilepticus. Drugs. 2015;75:1499–1521.
   PubMed Web of Science ®Google Scholar
• Trinka E, Brigo F. Benzodiazepines used in the treatment of epilepsy. Treat Epilepsy. 2015;4:398–417.
   Google Scholar
• Prasad M, Krishnan PR, Sequeira R, et al. Anticonvulsant therapy for status epilepticus. Cochrane Database Syst Rev. 2014;2014:CD003723.
   Google Scholar
• Arya R, Gulati S, Kabra M, et al. Intranasal versus intravenous lorazepam for control of acute seizures in children: a randomized open-label study. Epilepsia. 2011;52:788–793.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Shader RI, Franke K, et al. Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. J Pharm Sci. 1979;68:57–63.
   PubMed Web of Science ®Google Scholar
• Wermeling DPH, Miller JL, Archer SM, et al. Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration. J Clin Pharmacol. 2001;41:1225–1231.
   PubMed Web of Science ®Google Scholar
• Chung JY, Cho JY, Yu KS, et al. Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. Clin Pharmacol Ther. 2005;77:486–494.
   PubMed Web of Science ®Google Scholar
• Olkkola KT, Ahonen J. Midazolam and other benzodiazepines. Handb Exp Pharmacol. 2008;182:335–360.
   PubMedGoogle Scholar
• Diep U, Chudow M, Sunjic KM. Pharmacokinetic changes in liver failure and impact on drug therapy. AACN Adv Crit Care. 2017;28:93–101.
   PubMed Web of Science ®Google Scholar
• Vidaurre J, Gedela S, Yarosz S. Antiepileptic drugs and liver disease. Pediatr Neurol. 2017;77:23–36.
   PubMed Web of Science ®Google Scholar
• Anderson GD, Hakimian S. Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment. Clin Pharmacokinet. 2014;53:29–49.
   PubMed Web of Science ®Google Scholar
• Morrison G, Chiang ST, Koepke HH, et al. Effect of renal impairment and hemodialysis on lorazepam kinetics. Clin Pharmacol Ther. 1984;35:646–652.
   PubMed Web of Science ®Google Scholar
• Swart EL, De Jongh J, Zuideveld KP, et al. Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. Am J Kidney Dis. 2005;45:360–371.
   PubMed Web of Science ®Google Scholar
• Currie CA, Ashley C. The renal drug handbook. Third ed. CRC Press; Taylor and Francis Group. 2008.
   Google Scholar
• Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American epilepsy society. Epilepsy Curr. 2016;16:48–61.
   PubMed Web of Science ®Google Scholar
• Abernethy DR, Greenblatt DJ, Divoll M, et al. Prolonged accumulation of diazepam in obesity. J Clin Pharmacol. 1983;23:369–376.
   PubMed Web of Science ®Google Scholar
• Andersson T, Miners J, Veronese M, et al. Diazepam metabolism by human liver microsomes is mediated by both S‐ mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol. 1994;38:131–137.
   PubMed Web of Science ®Google Scholar
• Mandelli M, Tognoni G, Garattini S. Clinical Pharmacokinetics of Diazepam. Clin Pharmacokinet. 1978;3:72–91.
   PubMed Web of Science ®Google Scholar
• Ochs HR, Greenblatt DJ, Eckardt B, et al. Repeated diazepam dosing in cirrhotic patients: cumulation and sedation. Clin Pharmacol Ther. 1983;33:471–476.
   PubMed Web of Science ®Google Scholar
• Brigo F, Nardone R, Tezzon F, et al. A common reference-based indirect comparison meta-analysis of buccal versus intranasal midazolam for early status epilepticus. CNS Drugs. 2015;29:741–757.
   PubMed Web of Science ®Google Scholar
• McMullan J, Sasson C, Pancioli A, et al. Midazolam versus diazepam for the treatment of status epilepticus in children and young adults: a meta-analysis. Acad Emerg Med. 2010;17:575–582.
   PubMed Web of Science ®Google Scholar
• Rai S, Drislane FW. Treatment of refractory and super-refractory status epilepticus. Neurotherapeutics. 2018;15:697–712.
   PubMed Web of Science ®Google Scholar
• Singhi S, Murthy A, Singhi P, et al. Continuous midazolam versus diazepam infusion for refractory convulsive status epilepticus. J Child Neurol. 2002;17:106–110.
   PubMed Web of Science ®Google Scholar
• Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain. 2011;134:2802–2818.
   PubMed Web of Science ®Google Scholar
• Holtkamp M. Pharmacotherapy for refractory and super-refractory status epilepticus in adults. Drugs. 2018;78:307–326.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Abernethy DR, Locniskar A, et al. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology. 1984;61:27–35.
   PubMed Web of Science ®Google Scholar
• Thummel KE, O’Shea D, Paine MF, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther. 1996;59:491–502.
   PubMed Web of Science ®Google Scholar
• Seo KA, Bae SK, Choi YK, et al. Metabolism of 1′- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7. Drug Metab Dispos. 2010;38:2007–2013.
   PubMed Web of Science ®Google Scholar
• Pentikainen PJ, Valisalmi L, Himberg JJ, et al. Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. J Clin Pharmacol. 1989;29:272–277.
   PubMed Web of Science ®Google Scholar
• Macgilchrist AJ, Birnie GG, Cook A, et al. Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis. Gut. 1986;27:190–195.
   PubMed Web of Science ®Google Scholar
• Vinik HR, Reves JG, Greenblatt DJ, et al. The pharmacokinetics of midazolam in chronic renal failure patients. Anesthesiology. 1983;59:390–394.
   PubMed Web of Science ®Google Scholar
• Driessen JJ, Vree TB, Guelen PJM. The effects of acute changes in renal function on the pharmacokinetics of midazolam during long-term infusion in ICU patients. Acta Anaesthesiol Belg. 1991;42:149–155.
   PubMedGoogle Scholar
• Nolin TD, Frye RF, Le P, et al. ESRD impairs nonrenal clearance of fexofenadine but not midazolam. J Am Soc Nephrol. 2009;20:2269–2276.
   PubMed Web of Science ®Google Scholar
• Aguglia U, Tinuper P, Gastaut H. Long-term effect of clobazam in therapy resistant reflex seizures. In: Reflex seizures and reflex epilepsies. Geneve: Médecine & Hygiène; 1989. p. 431–438.
   Google Scholar
• Ng YT, Collins SD. Clobazam. Neurotherapeutics. 2007;4:138–144.
   PubMed Web of Science ®Google Scholar
• Mahmoud SH, Rans C. Systematic review of clobazam use in patients with status epilepticus. Epilepsia Open. 2018;3:323–330.
   PubMedGoogle Scholar
• Tinuper P, Aguglia U, Gastaut H. Use of clobazam in certain forms of status epilepticus and in startle-induced epileptic seizures. Epilepsia. 1986;27:S18–S26.
   PubMed Web of Science ®Google Scholar
• Sivakumar S, Ibrahim M, Parker D, et al. Clobazam: an effective add-on therapy in refractory status epilepticus. Epilepsia. 2015;56:e83–e89.
   PubMed Web of Science ®Google Scholar
• Tolbert D, Bekersky I, Chu HM, et al. An integrative population pharmacokinetics approach to the characterization of the effect of hepatic impairment on clobazam pharmacokinetics. J Clin Pharmacol. 2016;56:213–222.
   PubMed Web of Science ®Google Scholar
• Alvarez V, Lee JW, Drislane FW, et al. Practice variability and efficacy of clonazepam, lorazepam, and midazolam in status epilepticus: a multicenter comparison. Epilepsia. 2015;56:1275–1285.
   PubMed Web of Science ®Google Scholar
• Thomson A. Fosphenytoin for the treatment of status epilepticus: an evidence-based assessment of its clinical and economic outcomes. Core Evid. 2005;1:65–75.
   PubMedGoogle Scholar
• Fischer JH, Patel TV, Fischer PA. Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures. Clin Pharmacokinet. 2003;42:33–58.
   PubMed Web of Science ®Google Scholar
• Vanholder R, Van Landschoot N, De Smet R, et al. Drug protein binding in chronic renal failure: evaluation of nine drugs. Kidney Int. 1988;33:996–1004.
   PubMed Web of Science ®Google Scholar
• Adler DS, Martin E, Gambertoglio JG, et al. Hemodialysis of phenytoin in a uremic patient. Clin Pharmacol Ther. 1975;18:65–69.
   PubMed Web of Science ®Google Scholar
• Jodoin K. The renal drug handbook: the ultimate prescribing guide for renal practitioners. 4th edition; CRC Press, Taylor and Francis Group, 2016.
   Google Scholar
• Yasiry Z, Shorvon SD. How phenobarbital revolutionized epilepsy therapy: the story of phenobarbital therapy in epilepsy in the last 100 years. Epilepsia. 2012;53:26–39.
   PubMed Web of Science ®Google Scholar
• Hocker S, Clark S, Britton J. Parenteral phenobarbital in status epilepticus revisited: mayo clinic experience. Epilepsia. 2018;59:193–197.
   PubMed Web of Science ®Google Scholar
• Yasiry Z, Shorvon SD. The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies. Seizure. 2014;23:167–174.
   PubMed Web of Science ®Google Scholar
• Sánchez Fernández I, Gaínza-Lein M, Lamb N, et al. Meta-analysis and cost-effectiveness of second-line antiepileptic drugs for status epilepticus. Neurology. 2019;14(92): e2339–e48.
   Google Scholar
• Brigo F, Igwe SC, Nardone R, et al. A common reference-based indirect comparison meta-analysis of intravenous valproate versus intravenous phenobarbitone for convulsive status epilepticus. Epileptic Disord. 2013;15:314–323.
   PubMed Web of Science ®Google Scholar
• Nelson E, Powell JR, Conrad K, et al. Phenobarbital pharmacokinetics and bioavailability in adults. J Clin Pharmacol. 1982;22:141–148.
   PubMed Web of Science ®Google Scholar
• Cullis B, Abdelraheem M, Abrahams G, et al. Peritoneal dialysis for acute kidney injury. Perit Dial Int. 2014;34:494–517.
   PubMedGoogle Scholar
• Kapur J, Elm J, Chamberlain JM, et al. Randomized trial of three anticonvulsant medications for status epilepticus. N Engl J Med. 2019;381:2103–2113.
   PubMed Web of Science ®Google Scholar
• Hönack D, Löscher W. Intravenous valproate: onset and duration of anticonvulsant activity against a series of electroconvulsions in comparison with diazepam and phenytoin. Epilepsy Res. 1992;13:215–221.
   PubMed Web of Science ®Google Scholar
• Romoli M, Mazzocchetti P, D’Alonzo R, et al. Valproic acid and epilepsy: from molecular mechanisms to clinical evidences. Curr Neuropharmacol. 2018;17:926–946.
   Web of Science ®Google Scholar
• Trinka E, Höfler J, Zerbs A, et al. Efficacy and safety of intravenous valproate for status epilepticus: a systematic review. CNS Drugs. 2014;28:623–639.
   PubMed Web of Science ®Google Scholar
• Brigo F, Storti M, Del Felice A, et al. IV Valproate in generalized convulsive status epilepticus: a systematic review. Eur J Neurol. 2012;19:1180–1191.
   PubMed Web of Science ®Google Scholar
• Verrotti A, Mencaroni E, Cofini M, et al. Valproic acid metabolism and its consequences on sexual functions. Curr Drug Metab. 2016;17:573–581.
   PubMed Web of Science ®Google Scholar
• Levy RH, Mattson RH, Meldrum BS, et al. Antiepileptic drugs. 5thedition. Lippincott Williams & Wilkins; 2002.
   Google Scholar
• Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2002;16:695–714.
   PubMed Web of Science ®Google Scholar
• Trinka E, Höfler J, Leitinger M, et al. Pharmacologic treatment of status epilepticus. Expert Opin Pharmacother. 2016;17:513–534.
   PubMed Web of Science ®Google Scholar
• Sztajnkrycer MD. Valproic acid toxicity: overview and management. J Toxicol Clin Toxicol. 2002;40:789–801.
   PubMed Web of Science ®Google Scholar
• Ruiz-Giménez J, Sánchez-Álvarez JC, Cañadillas-Hidalgo F, et al. Antiepileptic treatment in patients with epilepsy and other comorbidities. Seizure. 2010;19:375–382.
   PubMed Web of Science ®Google Scholar
• Bansal AD, Hill CE, Berns JS. Use of antiepileptic drugs in patients with chronic kidney disease and end stage renal disease. Semin Dial. 2015;28:404–412.
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Ghattaura S, Ratnaraj N, et al. In situ metabolism of levetiracetam in blood of patients with epilepsy. Epilepsia. 2006;47:1818–1821.
   PubMedGoogle Scholar
• Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43:707–724.
   PubMed Web of Science ®Google Scholar
• Lapmag A, Lertsinudom S, Chaiyakam A, et al. Clinical outcomes of intravenous levetiracetam treatment in patients with renal impairment. Neurol Int. 2018 Sep;25(10):7469.
   Google Scholar
• French J. Use of levetiracetam in special populations. Epilepsia. 2001;42(4):40–43.
   PubMedGoogle Scholar
• Strzelczyk A, Zöllner JP, Willems LM, et al. Lacosamide in status epilepticus: systematic review of current evidence. Epilepsia. 2017;58:933–950.
   PubMed Web of Science ®Google Scholar
• Parviainen I, Uusaro A, Kälviäinen R, et al. High-dose thiopental in the treatment of refractory status epilepticus in intensive care unit. Neurology. 2002;59:1249–1251.
   PubMed Web of Science ®Google Scholar
• Dundee JW. Thiopentone narcosis in the presence of hepatic dysfunction. Br J Anaesth. 1952;24:81–100.
   PubMedGoogle Scholar
• Christensen JH, Andreasen F, Jansen JA. Pharmacokineticsand pharmacodynamics of thiopental in patients undergoing renal transplantation. Acta Anaesthesiol Scand. 1983;27:513–518.
   PubMed Web of Science ®Google Scholar
• Brown AS, Horton JM. Status epilepticus treated by intravenous infusions of thiopentone sodium. BMJ. 1967;1:27–28.
   PubMedGoogle Scholar
• Ferlisi M, Shorvon S. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain. 2012;135:2314–2328.
   PubMed Web of Science ®Google Scholar
• Wu J, Huang SQ, Chen QL, et al. The influence of the severity of chronic virus-related liver disease on propofol requirements during propofol-remifentanil anesthesia. Yonsei Med J. 2013;54:231–237.
   PubMed Web of Science ®Google Scholar
• Ickx B, Cockshott ID, Barvais L, et al. Propofol infusion for induction and maintenance of anaesthesia in patients with end-stage renal disease. Br J Anaesth. 1998;81:854–860.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Bae J, Kwon Y, et al. General anesthetic agents and renal function after nephrectomy. J Clin Med. 2019;8:1530.
   Web of Science ®Google Scholar
• Gaspard N, Foreman B, Judd LM, et al. Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study. Epilepsia. 2013;54:1498–1503.
   PubMed Web of Science ®Google Scholar
• Höfler J, Rohracher A, Kalss G, et al. (S)-Ketamine in refractory and super-refractory status epilepticus: a retrospective study. CNS Drugs. 2016;30:869–876.
   PubMed Web of Science ®Google Scholar
• Sabharwal V, Ramsay E, Martinez R, et al. Propofol-ketamine combination therapy for effective control of super-refractory status epilepticus. Epilepsy Behav. 2015;52:264–266.
   PubMed Web of Science ®Google Scholar
• Mahmoud SH. Antiepileptic drug removal by continuous renal replacement therapy: a review of the literature. Clin Drug Investig. 2017 Jan;37:7–23.
   PubMed Web of Science ®Google Scholar
• Smetana KS, Cook AM, Bastin ML, et al. Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy. J Crit Care. 2016 Dec;1(36):116–124.
   Google Scholar
• Ferlazzo E, Russo E, Mumoli L, et al. Profile of brivaracetam and its potential in the treatment of epilepsy. Neuropsychiatr Dis Treat. 2015;11:2967–2973.
   PubMed Web of Science ®Google Scholar
• Mumoli L, Palleria C, Gasparini S, et al. Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures. Drug Des Devel Ther. 2015;9:5719–5725.
   PubMed Web of Science ®Google Scholar
• Brigo F, Lattanzi S, Nardone R, et al. Intravenous brivaracetam in the treatment of status epilepticus: a systematic review. CNS Drugs. 2019;33:771–781.
   PubMed Web of Science ®Google Scholar
• Santamarina E, Parejo Carbonell B, Sala J, et al. Use of intravenous brivaracetam in status epilepticus: a multicenter registry. Epilepsia. 2019;60:1593–1601.
   PubMed Web of Science ®Google Scholar
• Hanada T, Ido K, Kosasa T. Effect of perampanel, a novel AMPA antagonist, on benzodiazepine-resistant status epilepticus in a lithium-pilocarpine rat model. Pharmacol Res Perspect. 2014;2:e00063.
   PubMedGoogle Scholar
• Citraro R, De Sarro C, Leo A, et al. Perampanel chronic treatment does not induce tolerance and decreases tolerance to clobazam in genetically epilepsy prone rats. Epilepsy Res. 2018;146:94–102.
   PubMed Web of Science ®Google Scholar
• Brigo F, Lattanzi S, Rohracher A, et al. Perampanel in the treatment of status epilepticus: a systematic review of the literature. Epilepsy Behav. 2018;86:179–186.
   PubMed Web of Science ®Google Scholar
• Farrokh S, Bon J, Erdman M, et al. Use of newer anticonvulsants for the treatment of status epilepticus. Pharmacotherapy. 2019;39:297–316.
   PubMed Web of Science ®Google Scholar
• Franco V, Crema F, Iudice A, et al. Novel treatment options for epilepsy: focus on perampanel. Pharmacol Res. 2013;70(1):35–40.
   PubMed Web of Science ®Google Scholar
• Laurenza A, Yang H, Williams B, et al. Absence of liver toxicity in perampanel-treated subjects: pooled results from partial seizure phase III perampanel clinical studies. Epilepsy Res. 2015;113:76–85.
   PubMed Web of Science ®Google Scholar